UniQure outlines AMT-130 confirmatory study of ~200 patients with May 1, 2027 PDUFA date in focus

Seeking Alpha · November 4, 2026, 19:05 UTC

Tickers: $QURE

Topics: clinical trials FDA approval gene therapy

Read the full article at Seeking Alpha

Part of the story UniQure outlines AMT-130 confirmatory study of ~200 patients with May 1, 2027 PDUFA date in focus (2 articles)

More World news

Broadcom Shares Rise Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 19:47 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 Motley Fool · November 12, 2026, 19:48 UTC
Team, Inc. (TISI) Reports Q3 2026 Results Amid Turnaround Deferrals and Geopolitical Disruptions Motley Fool · November 12, 2026, 19:44 UTC
Berkshire Hathaway Stock Reaches Record Levels Amid CEO Greg Abel's Leadership Motley Fool · November 12, 2026, 19:45 UTC
Data I/O Reports Q3 2026 Results Amid V-TEK Acquisition and Automotive Softness Motley Fool · November 12, 2026, 19:45 UTC
Google Unveils Gemini 4 Hydrogen AI Model Optimized for Coding Efficiency Seeking Alpha · November 12, 2026, 19:44 UTC
CMS Announces Final Valuations and Reimbursement Rates for New ESD CPT Codes PR Newswire · November 12, 2026, 19:43 UTC
IRS Announces 2027 Retirement Contribution Limits and Social Security COLA Increase Motley Fool · November 12, 2026, 19:37 UTC
Yesway Reaffirms 2026 EBITDA Guidance and Outlines Texas Allsup’s Conversion Timeline Seeking Alpha · November 12, 2026, 19:40 UTC
Boost Run Reports 496% Year-Over-Year Revenue Growth in Q3 2026 Seeking Alpha · November 12, 2026, 19:40 UTC